Decision to list medical devices supplied by Jackson Allison Medical & Surgical Limited
We are pleased to announce the approval of a listing agreement with Jackson Allison Medical & Surgical Limited for the supply of interventional radiology products; needles and syringes; and respiratory equipment and consumables.
In summary this will result in:
- Jackson Allison’s interventional radiology products, needles and syringes and respiratory care products being listed on the Pharmaceutical Schedule from 1 November 2018 under a national agreement that all DHBs may purchase under (“Agreement”).
- DHBs continuing to be able to purchase other suppliers’ brands of interventional radiology products, needles and syringes and respiratory care products.
Any changes to the original proposal?
This decision was subject to a consultation letter dated 27 August 2018.
No changes have been made to the listing Agreement as a result of consultation feedback.
Who we think will be most interested
- Suppliers and Wholesalers
- DHB Staff
- Clinical Engineers
- Interventional radiology staff
- Anaesthetists and Anaesthetic Technicians
- Clinical staff involved with airway management and emergency respiratory resuscitation
- Respiratory Clinicians
- Respiratory therapists
- Pulmonary function specialists
- Pulmonary rehabilitation specialists
- Clinical staff working in surgical and medical units, emergency departments, intensive and critical care units, and outpatient units
- District nurses
- Procurement Officers
Detail about this decision
In 2017 PHARMAC issued Requests for Proposals (“RFPs”) for:
The RFPs were for non-exclusive national agreements for listing in the Pharmaceutical Schedule.
After completing the RFP evaluation processes and consulting on the provisional Agreement reached with Jackson Allison, PHARMAC has decided to list Jackson Allison’s range of interventional radiology products, needles and syringes and respiratory care products in Part III of Section H of the Pharmaceutical Schedule.
DHBs that purchase Jackson Allison’s interventional radiology products, needles and syringes and respiratory care products must do so under the terms and conditions and at the prices included in the Agreement, from 1 November 2018. DHBs can continue to choose which interventional radiology products, needles and syringes and respiratory care products they purchase.
PHARMAC expects to consult on further agreements with suppliers of interventional radiology products, needles and syringes and respiratory care products over the next few months.
Our response to what you told us
We appreciate the time people took to consider this consultation.
A summary of the main themes raised in feedback and our responses to the feedback received are set out below:
Theme | Comment |
---|---|
Advising no technical resource impacts anticipated as a result of proposal. |
Noted. |
If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.